Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions
Maen Abdelrahim, Abdullah Esmail, Bandar Al-Judaibi, Ola Khorshid, Bhoori Sherrie, Vincenzo Mazzaferro · 2026
Read Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions by Maen Abdelrahim, Abdullah Esmail, Bandar Al-Judaibi, Ola Khorshid, Bhoori Sherrie, Vincenzo Mazzaferro (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13253381.txt.
Description
Maen Abdelrahim and colleagues review immune checkpoint inhibitors around liver transplantation for liver cancer in a 2026 transplant oncology article. These drugs can shrink hepatocellular carcinoma enough to bring patients within transplant criteria. The same immune activation that fights the tumor, however, can turn against the donated liver and trigger rejection.
Gathered retrospective data put rejection at roughly eighteen to twenty-six percent when the drugs were used before transplant, and higher still, twenty-eight to thirty-seven percent, when used afterward, with some cases fatal. A washout break of at least fifty to ninety days before surgery, ideally about three months, appears to soften the risk without erasing it. Living donor transplant helps because the operation date can be set precisely around the washout. Post-transplant use remains a case-by-case gamble reserved for careful decisions.
Catalog record
| CREATOR | Maen Abdelrahim, Abdullah Esmail, Bandar Al-Judaibi, Ola Khorshid, Bhoori Sherrie, Vincenzo Mazzaferro |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |